Skip to content

JOLYPHARMA: sector benchmark

Where does a company stand against its sector? Every ratio over five fiscal years, with its place among its peers and what that means, ready to print for your client.

Sector benchmark

JOLYPHARMA

BE 0473.899.537
NACE 47.730, Retail sale of pharmaceutical products
NACE division 47, Retail trade all sizesfiscal years 2021 to 202516,997 to 32,568 sector peers per ratio

Summary

fiscal year 2025

JOLYPHARMA does better than half of its sector on 8 of the 9 ratios compared.

most favourable quarter above the median below the median least favourable quarter
Strongest points
  • Quick ratiobetter than 92%
  • Current ratiobetter than 91%
  • Solvencybetter than 87%
Points to watch
  • Return on equitybetter than 45%

Solvency and debt

How soundly the company is financed.
Solvency
79.3%▲2025

Solvency is above 87% of 32,488 sector peers: in the most favourable quarter.

Position against the sector stable since 2021.

20212022202320242025
Debt to equity
0.26▼2025

Debt to equity is below 71% of 32,106 sector peers: more favourable than the median.

Position against the sector stable since 2021.

20212022202320242025
Long-term debt ratio
0.14▼2025

The long-term debt ratio is below 64% of 16,997 sector peers: more favourable than the median.

Position against the sector improving since 2021.

20212022202320242025
Interest coverage
25.36▲2025

Interest coverage is above 76% of 29,199 sector peers: in the most favourable quarter.

Position against the sector stable since 2021.

20212022202320242025

Liquidity

Whether it can pay its short-term bills.
Current ratio
6.76▲2025

The current ratio is above 91% of 32,316 sector peers: in the most favourable quarter.

Position against the sector stable since 2021.

20212022202320242025
Quick ratio
6.01▲2025

The quick ratio is above 92% of 32,337 sector peers: in the most favourable quarter.

Position against the sector stable since 2021.

20212022202320242025
Working-capital ratio
52.7%▲2025

The working-capital ratio is above 75% of 32,412 sector peers: in the most favourable quarter.

Position against the sector improving since 2021.

20212022202320242025

Profitability

What the company earns on its assets and its sales.
Return on equity
9.8%▼2025

Return on equity is below 55% of 27,017 sector peers: less favourable than the median.

Position against the sector stable since 2021.

20212022202320242025
Return on assets
7.8%▼2025

Return on assets is above 65% of 32,568 sector peers: more favourable than the median.

Position against the sector stable since 2021.

20212022202320242025

Not computable

Net margin, EBITDA margin, Gross margin, Days sales outstanding, Days payable outstanding, Days inventory. The filed figures do not contain the lines these need.

Source: filed annual accounts (NBB) and main activity (CBE register). Compared per fiscal year with each peer's latest statutory accounts; at least 30 peers per ratio. Prepared on 28 September 2026 via checked.be.